Table 2.
A summary of early phase trials of CAR-T and CAR-NK therapy. JMML: juvenile myelomonocytic leukemia, Rel./ref.: relapsed or refractory, CR: complete remission, CRh: CR with partial hematologic recovery, CRi: CR with incomplete hematologic recovery, MRD: minimal residual disease.
| Authors | Objects | Disease State | Agents | Target(s) | Phase | Clinical Outcome |
|---|---|---|---|---|---|---|
| Rithchie, et al., 2013 |
AML | Rel./ref. | CAR-T (2nd gen.) | Lewis-Y antigen | I | Transient decrease of blasts in 1 of 4 patients 14–38% of Transduction efficiency |
| Wang, et al., 2015 |
AML | Rel./ref. | CAR-T (2nd gen.) | CD33 | I | Marked reduction of marrow blasts for 9 weeks in 1 patient |
| Sallman, et al., 2018 |
Solid tumors and hematologic malignancies |
Rel./ref. | CAR-T | NKG2D | I | 1 CRh and 2 CRi of 7 patients with AML |
| Liu, et al., 2018 |
JMML | Rel./ref. | Compound CAR-T | CLL-1 and CD33 | I | CR with negative MRD in 1 patient |
| Tang, et al., 2018 |
AML | Rel./ref. | CAR-NK | CD33 | I | Decrease of MRD and WT-1 in 1 of 3 patients |